Esperion Therapeutics (ESPR) Misses Q4 EPS by 13c, Revenues Miss

February 23, 2021 4:43 PM EST
Get Alerts ESPR Hot Sheet
Price: $27.02 -0.07%

Today's EPS Names:
CVU, BK, KSU, More
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Esperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of ($3.89), $0.13 worse than the analyst estimate of ($3.76). Revenue for the quarter came in at $9.64 million versus the consensus estimate of $12.52 million.

“Even though 2020 was an exceptionally challenging year, we made progress in our mission of Lipid Management for Everyone. Successes include the U.S. FDA approval of NEXLETOL® and NEXLIZET®, our innovative oral, once-daily, non-statin LDL-C lowering medicines for indicated patients, the EU EMA approval of NILEMDO® and NUSTENDI® and the first-ever EU product royalty revenue from Daiichi Sankyo Europe, establishing a collaboration with another world-class partner for our medicines in Japan and making uninterrupted progress on our landmark CLEAR Outcomes trial in statin intolerant patients, all while battling the headwinds of the COVID-19 pandemic,” said Tim M. Mayleben, president and chief executive officer of ESPERION. “While navigating the unprecedented environment, we adjusted our commercial and operational footprint, while also optimizing our cost structure to position our team to realize the full potential of our medicines as the negative impact of the pandemic recedes. I am very optimistic for our future growth prospects.”

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Earnings, Management Comments

Related Entities

Earnings, FDA